Enliven Therapeutics
ELVN
ELVN
40 hedge funds and large institutions have $92.6M invested in Enliven Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
64% less capital invested
Capital invested by funds: $257M → $92.6M (-$164M)
Holders
40
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$2.65M | |
| 2 | +$430K | |
| 3 | +$377K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$169K |
| 5 |
Two Sigma Advisers
New York
|
+$139K |
Top Sellers
| 1 | -$7.95M | |
| 2 | -$4.21M | |
| 3 | -$3.08M | |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$206K |
| 5 |
Bank of New York Mellon
New York
|
-$68.9K |